ストックスクリーナーアプリを入手
447.54
0.10%
-0.43
アフターアワーズ：
447.54
前日終値:
$447.97
開ける：
$448.01
24時間の取引高:
1.89M
Relative Volume:
1.46
時価総額：
$113.59B
収益：
$12.34B
当期純損益:
$4.34B
株価収益率:
26.53
EPS:
16.8685
ネットキャッシュフロー:
$3.71B
1週間 パフォーマンス:
+3.00%
1か月 パフォーマンス:
+5.74%
6か月 パフォーマンス:
+3.21%
1年 パフォーマンス:
+0.10%
1日の値動き範囲:
$442.25
$450.00
1週間の範囲:
$433.79
$450.00
52週間の値動き範囲:
$362.50
$507.92
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.78 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
835.99 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.98 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.48 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-18 | アップグレード | Maxim Group | Hold → Buy |
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-03-10 | 繰り返されました | Oppenheimer | Outperform |
| 2026-02-13 | アップグレード | Oppenheimer | Perform → Outperform |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2026-01-06 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-25 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 開始されました | Raymond James | Mkt Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-09 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 開始されました | Redburn Atlantic | Buy |
| 2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-05-04 | 再開されました | Piper Sandler | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 繰り返されました | JP Morgan | Overweight |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
| 2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Hold |
| 2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
| 2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-30 | 開始されました | Daiwa Securities | Outperform |
| 2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 開始されました | Bernstein | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-09-03 | アップグレード | Goldman | Neutral → Buy |
| 2019-08-01 | ダウングレード | Needham | Buy → Hold |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | In-line |
| 2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Vertex Pharma stock (US92532F1003): Valuation stays in focus after a fresh move - AD HOC NEWS
VRTX: Renal franchise set to rival CF as new therapies and launches drive next phase of growth - TradingView
Vertex (VRTX) Announces Health Canada Acceptance of NDS for Suzetrigine - Insider Monkey
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals Inc stock (US92532F1003): Texas pension fund disclosure spotlights biotech he - AD HOC NEWS
These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth - Yahoo Finance
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - PR Newswire
Vertex’s Journavx made history, but left a void in the pain space - Pharma Voice
Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal - Fierce Pharma
Vertex Pharmaceuticals Incorporated Shs Cert Deposito Arg Repr 0.00990099 Shs - TradingView
Ending the Pharma Relay Race with a Non-Opioid Breakthrough - PharmExec.com
Truist assumes Vertex stock coverage with buy rating on kidney drugs - Investing.com
Vertex Pharma stock (US92532F1003): cystic fibrosis franchise underpins valuation as investors weigh - AD HOC NEWS
Is Vertex Pharmaceuticals Successfully Diversifying Beyond Cystic Fibrosis - Kavout
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - The Motley Fool
Vertex Pharmaceuticals lays off 125 workers in RI - MSN
Vertex Pharma stock (US92532F1003): Health Canada review for new pain drug puts pipeline in focus - AD HOC NEWS
Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Severe Acute Pain in Adults - BioSpace
VRTX: Vertex Pharmaceuticals Seeks Approval for New Pain Treatme - GuruFocus
What Are Wall Street Analysts' Target Price for Vertex Pharmaceuticals Stock? - Yahoo Finance
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness - Yahoo Finance
VRTX Stock Price Prediction 2025-2026 | Vertex Pharmaceuticals Inc Forecast - 24/7 Wall St.
Vertex Pharmaceuticals Earnings Call Highlights New Growth Engines - TipRanks
Vertex Pharma stock (US92532F1003): cystic fibrosis leader eyes new growth drivers after latest pipe - AD HOC NEWS
META_TITLE_QUOTE - Yahoo Finance
Vertex Pharma stock (US92532F1003): cystic fibrosis leader eyes gene-editing future - AD HOC NEWS
Vertex Pharmaceuticals’ SWOT analysis: kidney drug stock draws mixed views - Investing.com Australia
J&J’s Duato makes 358 times his median employee; Vertex CEO makes just 80 times - BioSpace
Vertex Pharma stock (US92532F1003): insider selling puts focus on biotech heavyweight - AD HOC NEWS
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals Inc (VRTX) Stock Price, Trades & News - GuruFocus
Vertex Pharmaceuticals Insider Sold Shares Worth $613,971, According to a Recent SEC Filing - Moomoo
VRTX: CF and pipeline innovation drive growth, with JOURNAVX and Povi poised for major impact - TradingView
Vertex (VRTX) CSO Mark Bunnage sells 33 shares in pre-set 10b5-1 trade - Stock Titan
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex Pharma stock (US92532F1003): cystic fibrosis leader after solid quarterly results - AD HOC NEWS
North Dakota State Investment Board Buys Shares of 8,821 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Canada Post Corp Registered Pension Plan Has $2.94 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma stock (US92532F1003): focus on cystic fibrosis and expanding pipeline - AD HOC NEWS
Vertex Pharma stock (US92532F1003): institutional flows and pipeline keep focus on biotech heavyweig - AD HOC NEWS
Vertex Pharmaceuticals stock (US92532F1003): gene-editing hopes meet kidney data buzz - AD HOC NEWS
Leuthold Group LLC Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
STF Management LP Lowers Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (VX1.DE) Stock Price, News, Quote & History - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX.VI) Stock Price, News, Quote & History - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by DNB Asset Management AS - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Allworth Financial LP Has $6.36 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vertex Pharma stock (US92532F1003): Q1 numbers, ESOP shelf and gene-editing momentum draw investor f - AD HOC NEWS
Vertex Pharmaceuticals (NASDAQ: VRTX) insider files Form 144 to sell vested shares - Stock Titan
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
1.84%
大文字化:
|
ボリューム (24 時間):